FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage ...
Why Alzheimer’s Scientists Are Re-thinking the Amyloid Hypothesis
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Rolling Out3d
5 ways this cancer drug could revolutionize Alzheimer’s treatment
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
BREAKTHROUGH IN TREATING ALZHEIMER'S DISEASE
Alzheimer's disease is a disorder of the brain that results in cognitive decline and is the main cause of dementia. Two types of early-stage Alzheimer's disease drugs were in practical use in Japan as ...
Elucidation Of Part Of The Mechanism By Which Lecanemab Slows The Progression Of Alzheimer's Disease
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's <a target=_blank href= ...
Reuters9d
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...